Immunotherapy drugs with cetuximab for treatable mouth cancer
Part of Cancer clinical trials.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus cetuximab for people with oral cancer that can be removed by surgery. The goal is to see if this treatment shrinks tumors and helps patients before their operation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with stage 3 or 4a oral squamous cell carcinoma (a type of mouth cancer) that can be surgically removed.
- Your cancer has at least one measurable tumor (seen on a CT scan, at least 10 mm in size).
- You are in good enough health to participate (able to do daily activities, with normal organ function).
- You have not had prior treatment with certain immunotherapy drugs (like PD-1/PD-L1/CTLA-4 inhibitors).
- You are willing to use effective birth control if you are of childbearing age.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immune-boosting cells and a targeted antibody to treat advanced head and neck cancer that has returned or spread. The goal is to see if this approach can shrink tumors or slow the disease.
This trial tests three drugs (finotonlimab, cetuximab, and docetaxel) given before surgery to remove recurrent head and neck cancer in patients whose cancer stopped responding to previous immunotherapy. The goal is to shrink the tumor and improve surgical outcomes.
This trial tests two newer drugs (one targeted therapy, one immunotherapy) given before surgery to shrink mouth cancer and improve outcomes. The goal is to see if combining them is safe and effective for people with stage III-IVA disease.
This trial tests whether combining two medicines – sintilimab (an immunotherapy) and cetuximab (a targeted therapy) – given before and after surgery can help treat advanced mouth or throat cancer. The study aims to see if this approach is safe and effective for patients whose cancer has not spread.
This trial tests two new immunotherapy drugs, iparomlimab and tuvonralimab, for people with head and neck squamous cell cancer that has spread or come back after at least 2 prior treatments. The goal is to see if this combination can shrink or slow the cancer.
This trial tests a combination of drugs (tislelizumab, cetuximab, and chemotherapy) before and after surgery for people whose mouth or throat cancer has returned after previous treatment. The goal is to see if this approach can help shrink or control the cancer and improve outcomes.
Hear when a new Head and Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.